 Pre-Exposure Prophylaxis
"Pre-Exposure Prophylaxis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of disease prevention (abbreviated PrEP) which involves the administration of drugs to at-risk persons who have not been exposed to the disease-causing agent.
| Descriptor ID |
D065129
|
| MeSH Number(s) |
N02.421.726.758.655 N06.850.780.680.655
|
| Concept/Terms |
Pre-Exposure Prophylaxis- Pre-Exposure Prophylaxis
- Pre Exposure Prophylaxis
- Pre-Exposure Prophylaxi
- Prophylaxi, Pre-Exposure
- Prophylaxis, Pre-Exposure
- Pre-Exposure Prophylaxis (PrEP)
- Pre Exposure Prophylaxis (PrEP)
- Pre-Exposure Prophylaxi (PrEP)
- Prophylaxi, Pre-Exposure (PrEP)
- Prophylaxis, Pre-Exposure (PrEP)
|
Below are MeSH descriptors whose meaning is more general than "Pre-Exposure Prophylaxis".
Below are MeSH descriptors whose meaning is more specific than "Pre-Exposure Prophylaxis".
This graph shows the total number of publications written about "Pre-Exposure Prophylaxis" by people in this website by year, and whether "Pre-Exposure Prophylaxis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 3 | 1 | 4 | | 2015 | 3 | 2 | 5 | | 2016 | 9 | 0 | 9 | | 2017 | 13 | 2 | 15 | | 2018 | 16 | 5 | 21 | | 2019 | 10 | 5 | 15 | | 2020 | 9 | 4 | 13 | | 2021 | 28 | 2 | 30 | | 2022 | 18 | 0 | 18 | | 2023 | 14 | 0 | 14 | | 2024 | 15 | 1 | 16 | | 2025 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Pre-Exposure Prophylaxis" by people in Profiles.
-
Meyers K, Lane B, Zucker J, Wu Y, Carnevale C, Burnside H, Rowan S, Mayes E, Narcisse-Cempini G, Gold MA, Saldana L, Golub SA. A case study of the co-creation of the PrEP-SIC: a roadmap to support introduction of pre-exposure prophylaxis into new settings. BMC Health Serv Res. 2025 May 01; 25(1):631.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. J Int AIDS Soc. 2025 Apr; 28(4):e26445.
-
Noguchi LM, Owor M, Mgodi NM, Gati Mirembe B, Dadabhai S, Horne E, Gundacker H, Richardson BA, Bunge K, Scheckter R, Song M, Marzinke MA, Anderson PL, Livant E, Jacobson C, Piper JM, Chakhtoura N, Hillier SL, Balkus JE. Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial. Lancet HIV. 2025 Mar; 12(3):e180-e190.
-
McGarrity MW, MacPherson P, Li A, Naccarato M, Anderson P, Tan DHS. Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery. HIV Med. 2025 Apr; 26(4):643-649.
-
Ybarra ML, Feaster DJ, Garofalo R, Bull S. Sexual Health Advocacy for Guys (SHAG): a randomized trial of the impact of a text-messaging program on HIV incidence and STI testing among a national sample of sexual minority cisgender?adolescent and young adult men. Trials. 2025 Jan 06; 26(1):9.
-
Ho K, Hoesley C, Anderson PL, Fern?ndez-Romero JA, Friedland BA, Kelly CW, Jiao Y, Edick S, Brand R, Kunjara Na Ayudhya RP, Zyhowski A, Hartman DJ, Reddy NB, Al-Khouja A, Piper J, Bauermeister JA, Teleshova N, Melo C, Cornejal N, Barnable P, Singh D, Scheckter R, McClure T, Hillier SL, Hendrix CW. Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037). J Acquir Immune Defic Syndr. 2024 Dec 01; 97(4):379-386.
-
Rozansky H, Christine PJ, Younkin M, Fox JM, Weinstein ZM, Suarez S, Stewart J, Farrell N, Taylor JL. Addiction consult service involvement in PrEP and PEP delivery for patients who inject drugs admitted to an urban essential hospital. Addict Sci Clin Pract. 2024 Nov 04; 19(1):77.
-
Gichane MW, Velloza J, Hosek S, Beauchamp G, Anderson P, Delany-Moretlwe S, Celum C. Hoping to Adhere? Examining the Relationship Between Hope and Pre-exposure Prophylaxis Willingness, Adherence, and Persistence Among Young Women in South Africa and Zimbabwe (HPTN 082). AIDS Behav. 2025 Feb; 29(2):527-534.
-
van den Elshout MAM, Wijstma ES, Boyd A, Jongen V, Coyer L, Anderson PL, Davidovich U, de Vries HJC, Prins M, Schim van der Loeff MF, Hoornenborg E. [Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men (MSM) using daily and event-driven pre-exposure prophylaxis (PrEP): Four-year follow-up of the Amsterdam PrEP (AMPrEP) demonstration project cohort]. Ned Tijdschr Geneeskd. 2024 10 21; 168.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|